Related Experiment Videos
[Tumors of the anus]
V Giordanello1, V Sorisio, A Zappa
1Divisione di Chirurgia Generale, U.S.S.L. n. 65, Ospedale Civile S. Lazzaro, Alba, Cuneo.
Minerva Chirurgica
|May 15, 1990
Summary
A new treatment protocol using mitomycin and 5-fluorouracil with local tumor removal offers a viable alternative to Miles amputation for anal tumors. This approach improves patient quality of life without compromising cancer survival rates.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Context:
- Anal tumors present a significant clinical challenge, often requiring radical surgical intervention.
- The Miles anorectal amputation is a traditional, yet highly morbid, treatment option.
- Evaluating alternative therapeutic strategies is crucial for improving patient outcomes.
Purpose:
- To assess the efficacy of a neoadjuvant polychemotherapy regimen (mitomycin and 5-fluorouracil) combined with local tumor excision for anal tumors.
- To compare this protocol with the standard Miles anorectal amputation in terms of oncological outcomes and quality of life.
Summary:
- A personal series analysis of anal tumors suggests that the Nigro et al. protocol (mitomycin, 5-fluorouracil, and local excision) is a potential alternative to Miles amputation.
- This organ-sparing approach demonstrated comparable oncological radicality and survival rates to traditional amputation.
- The proposed treatment significantly enhances the patient's quality of life.
Impact:
- This research indicates a shift towards less invasive, function-preserving treatments for anal cancer.
- The findings support the adoption of combined chemoradiotherapy and local excision protocols, potentially reducing the need for abdominoperineal resection.
- Improved quality of life for anal cancer survivors is a key benefit of this therapeutic strategy.